Goal: Develop and fund a series of three-year FLC research fellowships
Grant length: Four years
Overview: This grant extended FCF’s successful partnership with the prestigious Cancer Research Institute (CRI) to identify and staff three-year research fellowships for young researchers focusing on immunotherapy-related research for fibrolamellar. CRI has been promoting immunotherapy research for 65 years, long before the establishment cancer treatment and research community recognized immunotherapy as a legitimate prospect for cancer patients.
Under the program, CRI identifies and screens potential candidates for the joint FCF/CRI fellowships. Those candidates learns about the opportunity and apply through CRI’s existing Postdoctoral Fellowship Program process. FCF then approves and funds the joint FCF/CRI fellowships for selected researchers who have a FLC-specific research focus. The overall goal of the program is to identify and attract promising early-career researchers to investigate our disease.
Results: The recent joint FCF/CRI fellowships that have been established through this grant extension include:
- Francisco Navarro, PhD (Albert Einstein)
- Lindsay Dickerson, MD (University of Washington)